Assenagon Asset Management S.A. Increases Stock Position in Accuray Incorporated (NASDAQ:ARAY)

Assenagon Asset Management S.A. lifted its holdings in shares of Accuray Incorporated (NASDAQ:ARAY) by 28.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 212,330 shares of the medical equipment provider’s stock after purchasing an additional 47,331 shares during the period. Assenagon Asset Management S.A.’s holdings in Accuray were worth $420,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Foundry Partners LLC increased its position in Accuray by 51.3% during the third quarter. Foundry Partners LLC now owns 2,187,160 shares of the medical equipment provider’s stock worth $3,937,000 after buying an additional 741,900 shares in the last quarter. State Street Corp boosted its stake in shares of Accuray by 3.8% during the third quarter. State Street Corp now owns 1,894,287 shares of the medical equipment provider’s stock valued at $3,410,000 after acquiring an additional 70,008 shares during the last quarter. Barclays PLC increased its position in Accuray by 97.9% during the 3rd quarter. Barclays PLC now owns 210,819 shares of the medical equipment provider’s stock worth $380,000 after purchasing an additional 104,310 shares in the last quarter. BNP Paribas Financial Markets raised its stake in Accuray by 1,650.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 146,384 shares of the medical equipment provider’s stock valued at $263,000 after purchasing an additional 138,022 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Accuray by 489.1% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 277,859 shares of the medical equipment provider’s stock valued at $500,000 after purchasing an additional 230,695 shares in the last quarter. 64.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, StockNews.com lowered shares of Accuray from a “buy” rating to a “hold” rating in a research report on Friday, November 15th.

Accuray Trading Down 0.4 %

Shares of Accuray stock opened at $2.28 on Friday. The firm has a market cap of $229.30 million, a PE ratio of -13.41 and a beta of 1.47. The company has a quick ratio of 0.87, a current ratio of 1.63 and a debt-to-equity ratio of 3.59. Accuray Incorporated has a fifty-two week low of $1.40 and a fifty-two week high of $2.95. The business’s fifty day moving average is $2.04 and its two-hundred day moving average is $1.94.

Accuray (NASDAQ:ARAY) last issued its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported ($0.04) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.04). The firm had revenue of $101.55 million for the quarter, compared to analyst estimates of $98.10 million. Accuray had a negative return on equity of 36.93% and a negative net margin of 3.72%. During the same period last year, the company earned ($0.03) EPS. Analysts anticipate that Accuray Incorporated will post 0.01 earnings per share for the current year.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.